Tramadol associated with higher mortality in OA

Tramadol is associated with significantly higher mortality than non-steroidal antiinflammatory drugs in people with osteoarthritis, new research suggests.

The study enrolled 88,902 people aged at least 50 years with knee, hip or hand osteoarthritis who initially received tramadol, naproxen, diclofenac, celecoxib, etoricoxib or codeine in UK general practice. The proportion receiving tramadol rose from 3.4 per cent in 2000 to 11.1 per cent in 2013, then declined to 9.8 per cent in 2015.

During a one-year follow-up, all-cause mortality among tramadol users was between 23.5 and 36.2 per 1,000 person-years, depending on the drug used for comparison.

Mortality was 70 per cent higher than with celecoxib, 71 per cent higher compared with naproxen and 88 per cent higher than diclofenac. All-cause mortality among tramadol users was double that among etoricoxib (odds ratio 2.04), but not significantly different compared with codeine.

Patients taking tramadol, in general, were older and had a higher body mass index and longer duration of osteoarthritis. They also had more co-morbidities and used more concurrent medications and healthcare services. As a result, the authors say, “the present findings should be interpreted with caution, and future studies are needed”.

Recommended

Does OTC NRT still have a role in smoking cessation?

Does OTC NRT still have a role in smoking cessation?




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.